Judge Herndon Denies BIPI’s Motions to Dismiss
Defendant Boehringer Ingelheim Pharmaceutials, Inc. (“BIPI”) filed Motions to Dismiss in every case filed against the company. BIPI argued that the Plaintiffs failed to allege a cause of action in the Complaints against the company. BIPI argued in their Motions that the Pradaxa label properly warned against severe gastrointestinal bleeding, hemorrhagic stroke, and death (as a result of severe or excessive bleeding). In response, Schlichter Bogard and Denton, and a handful of firms located around the country, filed Oppositions to the Motions to Dismiss. Judge David Herndon, of the Southern District of Illinois, ruled in favor of the Plaintiffs on all counts. This means Plaintiffs are permitted to pursue their claims against BIPI.
By way of background, Pradaxa is a blood thinning (anticoagulant) prescription medication used to lower the chance of stroke in individuals with atrial fibrillation. Pradaxa was approved by the FDA in October 2010 and is manufactured by the Germany-based pharmaceutical company Boehringer Ingelheim. BIPI is the U.S. division of Boehringer Ingelheim responsible for the marketing and sales of Pradaxa.
Since approval, some studies have indicated the risk of gastrointestinal bleeding and hemorrhagic stroke is greater than what was reported in Boehringer Ingelheim’s label. Consequently, attorneys at Schlichter Bogard & Denton represent individuals in the Pradaxa litigation. If you or someone you know has been injured by Pradaxa, please contact the attorneys at Schlichter Bogard & Denton to discuss your case.